A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer
What is this summary about? Dostarlimab, also known by the brand name JEMPERLI, is a medicine that can be used to treat certain types of endometrial cancer. GARNET is an ongoing phase 1 clinical study that is testing the safety and side effects of dostarlimab and the best way to administer it to patients. The results presented in this summary are from a time point in the middle of the study. What were the results? The results from the GARNET study published in 2022 showed how well dostarlimab worked for people participating in the study. Dostarlimab was found to reduce the size of tumors in patients with certain types of endometrial cancer. The patients treated with dostarlimab had side effects that could be managed and few severe side effects. What do the results mean? The results of the GARNET study led to dostarlimab being approved to treat patients with certain types of endometrial cancer. For patients with advanced-stage endometrial cancer, or endometrial cancer that has come back after chemotherapy (recurrent), there are few treatment options. The results suggest that dostarlimab may provide long-term benefits for these patients.
Endometrial cancer; Gynecologic cancer; Immunotherapy
Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, et al. A Plain Language Summary of Results from the GARNET Study of Dostarlimab in Patients with Endometrial Cancer. Future Oncol. 2023 Aug;19(25):1709–14.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/10261
The following license files are associated with this item: